+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis



Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis



Lupus 22(14): 1489-1503



The wide spectrum of clinical manifestations and high relapse rate represent a therapeutic challenge in systemic lupus erythematosus (SLE). Observational studies suggested efficacy of rituximab (RTX), a B-cell-targeting antibody, to control the activity of SLE. Two randomized trials controlled by placebo did not prove the superiority of RTX when used in addition to conventional treatment in nonrenal (EXPLORER) and renal (LUNAR) lupus. A systematic review of studies exploring the efficacy of RTX in SLE patients was conducted. The pooled percentages of response were assessed. Thirty studies with 1243 patients were analyzed. In studies using the British Isles Lupus Assessment Group (BILAG), the complete response (CR) rate was 46.7% (95% CI 36.8%-56.8%) and the partial response (PR) was 37.9% (95% CI 30.6%-45.8%). With the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), the CR was 56.6% (95% CI 32.4%-78.1%) and the PR was 30.9% (95% CI 8.9%-46%). In renal lupus the CR was 36.1% (95% CI 25.2%-48.6%); PR was 37.4% (95% CI 28.5%-47.3%). In EXPLORER, CR was 12.4% and PR was 17.2%; in LUNAR CR was 26.4% and PR was 30.6%, in both cases not different from controls. Assessment and standardization of SLE response to treatment remain a challenge. The discrepancy in the perceived efficacy of RTX between controlled and observational studies reflects the heterogeneity of lupus and stringency in criteria of response. Further randomized trials focusing on selected SLE manifestations and using composite response indices are warranted.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055590169

Download citation: RISBibTeXText

PMID: 24135078

DOI: 10.1177/0961203313509295


Related references

Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. Journal of Zhejiang University. Science. B 13(9): 731-744, 2013

Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative meta-analysis. Clinical Rheumatology 34(11): 1885-1892, 2016

A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clinical Journal of the American Society of Nephrology 5(11): 2060-2068, 2011

Association between Systemic Lupus Erythematosus and Periodontitis: A Systematic Review and Meta-analysis. Frontiers in Immunology 8: 1295, 2017

Associations between TLR polymorphisms and systemic lupus erythematosus: a systematic review and meta-analysis. Clinical and Experimental Rheumatology 30(2): 262-265, 2012

Assessment of subclinical atherosclerosis in systemic lupus erythematosus: A systematic review and meta-analysis. Joint, Bone, Spine 85(2): 155-163, 2017

SAT0446The prevalence of systemic lupus erythematosus in europe: A systematic review and meta-analysis. Annals of the Rheumatic Diseases 71(Suppl 3): 623.1-623, 2013

SAT0389Assessment of Subclinical Atherosclerosis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. Annals of the Rheumatic Diseases 74(Suppl 2): 800.2-800, 2015

Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. Bmc Psychiatry 17(1): 70, 2017

Thrombocytopenia as a Prognostic Marker for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis. American Journal of the Medical Sciences 2019, 2019

Foot and ankle characteristics in systemic lupus erythematosus: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism 2018, 2018

Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clinical Rheumatology 29(7): 707-716, 2010

The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Arthritis Research and Therapy 20(1): 270, 2018

THU0344Osteoporosis and Vertebral Fractures in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. Annals of the Rheumatic Diseases 75(Suppl 2): 311.2-312, 2016

Prevalence of cervical HPV infection in women with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmunity Reviews 2018, 2018